9月10日 - ** 药物开发商 Travere Therapeutics TVTX.O 股价盘前上涨 22% 至 26.39 美元
** 该公司表示，美国FDA不再需要召开咨询委员会会议 (link)，以批准其肾病药物Filspari治疗局灶节段性肾小球硬化症（一种罕见肾病）的补充申请。
** 公司正在寻求扩大 Filspari 的批准范围，目标决定日期为 1 月 13 日。
** Filspari于2023年获批用于治疗IgA肾病，但附有肝损伤和出生缺陷的警示框。
** 上月 (link)，FDA 放宽了对 Filspari 的监测规定
** 截至上次收盘，股价累计上涨 24
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.